ALX Oncology Holdings Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ALX Oncology Holdings Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-174.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 88% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-16.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
+21%Cash, after subtracting all debt, equals 21% of its market value (net cash).
Higher than 63% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
ALX Oncology Holdings Inc. made a loss over the last year. ALX Oncology Holdings Inc. owes $0.15 for every $1 it owns. ALX Oncology Holdings Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossALX Oncology Holdings Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.19The share price is 1.19 times ALX Oncology Holdings Inc.'s book value per share, lower than 75% of Healthcare companies in United States.
Market cap
$162 MThe total market value of all of ALX Oncology Holdings Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$136 MWhat ALX Oncology Holdings Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.98Net worth divided by the number of shares. The share price of $1.17 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-80.7%ALX Oncology Holdings Inc. lost 80.7% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
Owes vs Owns
0.15×ALX Oncology Holdings Inc. owes $0.15 for every $1 it owns (low), lower than 79% of Healthcare companies in United States.
Dividend yield
NoneALX Oncology Holdings Inc. does not currently pay a dividend.
Profit growth
LossALX Oncology Holdings Inc. made a loss in each of the last two years.
Interest cover
Not coveredALX Oncology Holdings Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashALX Oncology Holdings Inc. held $35 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ALX Oncology Holdings Inc.: $162 M ÷ $136 M (30 Jun 2026) = 1.2.
What is ALX Oncology Holdings Inc.'s return on equity?
ALX Oncology Holdings Inc. lost 80.7% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
How much does ALX Oncology Holdings Inc. owe compared with what it owns?
ALX Oncology Holdings Inc. owes $0.15 for every $1 it owns (low), lower than 79% of Healthcare companies in United States.
Does ALX Oncology Holdings Inc. pay a dividend?
No. ALX Oncology Holdings Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.